Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters











Publication year range
1.
Rev. med. Chile ; 150(8): 1060-1062, ago. 2022. graf
Article in Spanish | LILACS | ID: biblio-1431875

ABSTRACT

BACKGROUND: COVID-19 impacted all areas of our society, and we took advantage of new technologies such as telemedicine to deliver information. Peer education is another tool that can be used. AIM: To report the experience of peer education among residents using a digital platform. MATERIAL AND METHODS: A digital educational program was devised in which third year residents exposed different relevant topics in internal medicine to their first year peers using Zoom. The educational process was evaluated using a Likert scale. RESULTS: A high level of satisfaction was found among the respondents according to the scale. Conclusions: There was a high level of satisfaction with the used methodology among first-year residents. A more exhaustive evaluation of this educational program should be worthwhile.


Subject(s)
Humans , COVID-19 , Internship and Residency , Education, Medical, Graduate , Internal Medicine
2.
Rev Med Chil ; 150(8): 1060-1062, 2022 Aug.
Article in Spanish | MEDLINE | ID: mdl-37358154

ABSTRACT

BACKGROUND: COVID-19 impacted all areas of our society, and we took advantage of new technologies such as telemedicine to deliver information. Peer education is another tool that can be used. AIM: To report the experience of peer education among residents using a digital platform. MATERIAL AND METHODS: A digital educational program was devised in which third year residents exposed different relevant topics in internal medicine to their first year peers using Zoom. The educational process was evaluated using a Likert scale. RESULTS: A high level of satisfaction was found among the respondents according to the scale. CONCLUSIONS: There was a high level of satisfaction with the used methodology among first-year residents. A more exhaustive evaluation of this educational program should be worthwhile.


Subject(s)
COVID-19 , Internship and Residency , Humans , Internal Medicine , Education, Medical, Graduate
3.
PLoS One ; 13(8): e0200835, 2018.
Article in English | MEDLINE | ID: mdl-30071030

ABSTRACT

Microcin E492 is a pore-forming bacteriocin with toxic activity against Enterobacteriaceae, which undergoes amyloid aggregation as a mechanism to regulate its toxicity. To be active, it requires the posttranslational attachment to the C-terminus of a glycosylated enterochelin derivative (salmochelin), a process carried out by the proteins MceC, MceI and MceJ encoded in the MccE492 gene cluster. Both microcin E492 and salmochelin have a proposed role in the virulence of the bacterial pathogen Klebsiella pneumoniae. Besides, enterochelin is produced as a response to low iron availability and its synthesis is controlled by the global iron regulator Fur. Since the production of active microcin E492 depends on enterochelin biosynthesis, both processes could be coordinately regulated. In this work, we investigated the role of Fur in the expression of the microcin E492 maturation genes mceCJI. mceC was not regulated by Fur as it occurs with its homolog iroB in Salmonella enterica. We demonstrated that mceJI along with the previously uncharacterized gene mceX are transcribed as a single mRNA, and that Fur binds in vivo to a Fur box located upstream of the mceX-mceJI unit. Also, we established that the expression of these genes decreased in a condition of high iron availability, while this effect is abrogated in a Δfur background. Furthermore, our results indicated that MceX acts as a negative regulator of microcin E492 structural gene expression, coupling its synthesis to the iron-dependent regulatory circuit. Consequently, fur or mceX overexpression led to a significant decrease in the antibacterial activity of cells producing microcin E492. Altogether these results show that both the expression of microcin E492 maturation genes mceJI, and MceX the negative regulator of microcin E492 synthesis, are coordinated with the enterochelin production by Fur, depending on the iron levels in the medium.


Subject(s)
Bacterial Proteins/metabolism , Bacteriocins/metabolism , Iron/metabolism , Repressor Proteins/metabolism , DNA, Recombinant , Escherichia coli , Gene Expression Regulation , Nucleotide Motifs , Protein Binding , Protein Processing, Post-Translational , RNA, Messenger/metabolism , Transcription, Genetic
4.
Int J Antimicrob Agents ; 44(4): 327-33, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25218157

ABSTRACT

Moxifloxacin is reported to have increased distribution into the prostate compared with older fluoroquinolones such as norfloxacin and ciprofloxacin, being able to reach tissue-to-plasma concentration ratios greater than unity. However, most of these studies use tissue homogenates derived from biopsy samples, which can lead to overestimation of free concentrations as fluoroquinolones tend to accumulate in the intracellular space. The aim of this study was to investigate moxifloxacin pharmacokinetics in rat prostate interstitial fluid by microdialysis. Tissue pharmacokinetics was assessed by implanting a small microdialysis catheter in the prostate gland. Blood samples were simultaneously collected for assessing plasma pharmacokinetics. Analysis of plasma (N=154) and microdialysis (N=344) concentrations after a single intravenous dose of 6 or 12mg/kg moxifloxacin was conducted in the non-linear mixed-effect modelling software NONMEM v.6 as well by a non-compartmental approach. Moxifloxacin showed a significant tissue distribution in the prostate (AUCprostate,ISF/fu·AUCplasma=1.24±0.37), 59% higher than the value obtained for levofloxacin in a previous study. A three-compartment model with non-linear kinetics could adequately describe moxifloxacin pharmacokinetics in terms of curve fitting and precision in parameter estimation. The developed pharmacokinetic model indicates that passive diffusion and active transport are the mechanisms involved in moxifloxacin distribution to the prostate. These findings suggest that moxifloxacin could be a better alternative to levofloxacin for the treatment of chronic bacterial prostatitis owing to its enhanced tissue penetration and higher AUCtissue/MIC ratios, even though it is not yet approved by the US FDA for this indication.


Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Fluoroquinolones/pharmacokinetics , Microdialysis , Prostate/chemistry , Administration, Intravenous , Animals , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/analysis , Fluoroquinolones/administration & dosage , Fluoroquinolones/analysis , Male , Models, Statistical , Moxifloxacin , Plasma/chemistry , Rats, Wistar , United States
5.
Antimicrob Agents Chemother ; 58(2): 678-86, 2014.
Article in English | MEDLINE | ID: mdl-24217697

ABSTRACT

Levofloxacin is a broad-spectrum fluoroquinolone used in the treatment of both acute and chronic bacterial prostatitis. Currently, the treatment of bacterial prostatitis is still difficult, especially due to the poor distribution of many antimicrobials into the prostate, thus preventing the drug to reach effective interstitial concentrations at the infection site. Newer fluoroquinolones show a greater penetration into the prostate. In the present study, we compared the unbound levofloxacin prostate concentrations measured by microdialysis to those in plasma after a 7-mg/kg intravenous bolus dose to Wistar rats. Plasma and dialysate samples were analyzed using a validated high-pressure liquid chromatography-fluorescence method. Both noncompartmental analysis (NCA) and population-based compartmental modeling (NONMEM 6) were performed. Unbound prostate tissue concentrations represented 78% of unbound plasma levels over a period of 12 h by comparing the extent of exposure (unbound AUC0-∞) of 6.4 and 4.8 h·µg/ml in plasma and tissue, respectively. A three-compartment model with simultaneous passive diffusion and saturable distribution kinetics from the prostate to the central compartment gave the best results in terms of curve fitting, precision of parameter estimates, and model stability. The following parameter values were estimated by the population model: V1 (0.38 liter; where V1 represents the volume of the central compartment), CL (0.22 liter/h), k12 (2.27 h(-1)), k21 (1.44 h(-1)), k13 (0.69 h(-1)), Vmax (7.19 µg/h), kM (0.35 µg/ml), V3/fuprostate (0.05 liter; where fuprostate represents the fraction unbound in the prostate), and k31 (3.67 h(-1)). The interindividual variability values for V1, CL, Vmax, and kM were 21, 37, 42, and 76%, respectively. Our results suggest that levofloxacin is likely to be substrate for efflux transporters in the prostate.


Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Levofloxacin/pharmacokinetics , Prostate/drug effects , Animals , Anti-Bacterial Agents/blood , Biological Availability , Blood Proteins/chemistry , Levofloxacin/blood , Male , Microdialysis , Permeability , Prostate/metabolism , Protein Binding , Rats , Rats, Wistar
6.
Repert. med. cir ; 20(2): 111-115, 2011. tab
Article in English, Spanish | LILACS, COLNAL | ID: lil-795527

ABSTRACT

Estudio descriptivo retrospectivo que busca valorar la frecuencia de infección en trauma craneoencefálico que fue manejado con esteroides. Se recolectó una muestra de 153 pacientes y de las historias clínicas se extrajeron las variables demográficas (edad, género, mortalidad) y las características clínicas (infección, uso de esteroides). Los resultados no evidenciaron aumento de la frecuencia de infecciones en los pacientes con trauma craneoencefálico que recibieron manejo con esteroides...


This descriptive retrospective study sought to assess the frequency of infectious complications in steroid recipients for central nervous system (CNS) trauma. A sample of 153 patients was collected and demographic variables (age, gender, mortality) and clinical features (infection, steroid use) were obtained from medical records. Results did not evidence an increase in the frequency of infectious complications in patients treated with steroids for CNS trauma...


Subject(s)
Humans , Male , Female , Middle Aged , Infections , Craniocerebral Trauma , Steroids , Mortality
7.
J AOAC Int ; 93(3): 869-75, 2010.
Article in English | MEDLINE | ID: mdl-20629389

ABSTRACT

A simple RP-HPLC method was developed and validated for the determination of rimonabant in a pharmaceutical dosage form. The separation was performed on a C18 column (150 x 4.6 mm id, 5 microm) with acetonitrile-water (75 + 25, v/v) mobile phase. The detection was achieved with a diode array detector at 215 nm. The method was linear in the concentration range of 0.5-50 microg/mL (r = 1) with an LOQ of 0.24 microg/mL. The specificity and stability-indicating capability of the method were proved through forced degradation studies, and it was shown that there was no increase of the cytotoxicity. Rimonabant was exposed to hydrolytic, oxidative, and photolytic stress conditions, and the samples were analyzed by the proposed method. Under optimized conditions, rimonabant was successfully separated from its degradation products within 10 min, and the resolution was found to be greater than 2. The RSD values for intraday and interday precision were always less than 2%. Interday accuracy ranged from 98.1 to 101.7% (RSD = 1.0%). Moreover, method validation demonstrated acceptable results for sensitivity and robustness. The method was applied for the quantitative analysis of rimonabant in a tablet dosage form to demonstrate its use for improving the QC of pharmaceuticals containing this drug.


Subject(s)
Cannabinoid Receptor Antagonists , Chromatography, High Pressure Liquid/methods , Piperidines/analysis , Pyrazoles/analysis , Animals , Drug Stability , Mice , Piperidines/chemistry , Piperidines/pharmacology , Pyrazoles/chemistry , Pyrazoles/pharmacology , Rimonabant , Tablets
8.
J Chromatogr Sci ; 48(5): 362-6, 2010.
Article in English | MEDLINE | ID: mdl-20515529

ABSTRACT

An isocratic high-performance liquid chromatographic (HPLC) method was developed and validated for the determination of bezafibrate in biological fluids. Bezafibrate was separated on a C(18) analytical column (150 x 4.6 mm i.d., 5 microm particle size) with 0.01 M phosphate buffer (pH 3.5)-acetonitrile-methanol (50:40:10) as mobile phase at a flow rate of 1.0 mL/min. The UV detector was set to 230 nm. Bezafibrate was extracted from human plasma using a simple liquid-liquid extraction with tert-butyl methyl ether. Parameters such as linearity, precision, accuracy, recovery, specificity, and stability were evaluated by method validation studies. All the parameters remained within acceptable limits. The validated procedure was linear in the concentration range of 0.2-50 microg/mL. The proposed method used for individual drug determinations is applicable for therapeutic monitoring purposes as well as for use in pharmacokinetic investigations. As an example, the practical quantification limit for bezafibrate in plasma was about 0.05 microg/mL with precision of 10.2% and accuracy of 112.6%. The method was applied in a study of the pharmacokinetics of bezafibrate in six healthy volunteers, who ingested a single oral dose of 200 mg.


Subject(s)
Bezafibrate/blood , Chromatography, High Pressure Liquid/methods , Hypolipidemic Agents/blood , Bezafibrate/pharmacokinetics , Humans , Hypolipidemic Agents/pharmacokinetics
SELECTION OF CITATIONS
SEARCH DETAIL